Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. BioElectronics Corporation (BIEL) Message Board

Formulary Inclusion When a product is added to

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 8492
(Total Views: 89)
Posted On: 07/18/2025 3:51:21 PM
Posted By: Bielionaire
Formulary Inclusion

When a product is added to the VA National Formulary, it becomes part of the official list of treatments that VA healthcare providers can prescribe. For ActiPatch and RecoveryRx, this means:

They’re recognized as approved therapies within the VA system.

VA clinicians can routinely prescribe them for pain management.

It streamlines access for veterans—no special approvals or workarounds needed.

This is a huge step toward mainstream adoption in federal healthcare.

Direct Reimbursement

Thanks to the NOPAIN for Veterans Act, these devices are now eligible for direct reimbursement by the VA. That means:

Veterans don’t pay out-of-pocket for these therapies.

BIEL receives payment directly from the government for each device used.

It creates a predictable revenue stream for BIEL, especially as usage scales.

This removes a major barrier to adoption and makes the devices more accessible.

VA Prescribing

VA doctors can now prescribe ActiPatch and RecoveryRx just like any other approved treatment. This opens up:

Widespread clinical use across pain management, orthopedics, physical therapy, and post-op recovery.

Integration into prosthetics programs, where RecoveryRx is already being used for residual limb pain.

A pathway for feedback and data collection from real-world use, which can further validate the technology.

The Big Picture

Together, these three milestones mean BIEL’s devices are:

Officially recognized by the VA

Financially supported by federal reimbursement

Clinically accessible to millions of veterans

It’s a trifecta that positions BIEL for explosive growth in the federal healthcare space.



(1)
(0)




BioElectronics Corporation (BIEL) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us